Everything You Need to Know About NSI-189: The Ultimate Guide for Canadian Researchers

Imagine a compound that could stimulate hippocampal neurogenesis, potentially reversing cognitive deficits in depression or stroke at doses as low as 40 mg daily—backed by Phase II trials showing modest hippocampal volume increases. As a Canadian researcher exploring neuroregeneration, major depressive disorder (MDD), or synaptic plasticity, NSI-189 emerges as a promising tool. Developed by Neuralstem, this benzylpiperazine-aminopyridine derivative offers monoamine-independent antidepressant effects. However, its investigational status demands ethical rigor. This guide synthesizes peer-reviewed data, applications, and compliant sourcing from ChemLabs Canada.

Disclaimer: NSI-189 is for legitimate research only. Not for human consumption. Consult Health Canada and REB protocols.

WHAT IS NSI-189?

NSI-189 (ALTO-100) is a neurogenic small molecule promoting hippocampal neurogenesis. Its chemical formula is C₂₂H₃₀N₄O, classifying it as a benzylpiperazine-aminopyridine. It stimulates neural stem cell proliferation, enhancing synaptic plasticity. For instance, researchers use it to model MDD recovery without serotonin modulation.

Chemical Structure Breakdown

NSI-189 comprises a pyridine core linked to piperazine and isopentylamino chains. The methanone bridge facilitates receptor interactions, boosting BDNF and SCF expression.

Common Synonyms

Called ALTO-100, Neuralstem 189, or NSI189. CAS: 1270138-40-3 (free base); phosphate salt (1270138-41-4) common.

Role in Research

Drives hippocampal volume growth in MDD models. Canadian labs require CCAC oversight for in vivo ethics.

HISTORY OF NSI-189

Discovered via high-throughput screening in 2008 by Neuralstem, NSI-189 targeted hippocampal neurogenesis for MDD. DARPA/NIH funding accelerated preclinical work.

Early Discovery

Screened against human fetal hippocampal stem cells; patented 2010.

Scientific Milestones

• 2011: Phase I safety in 41 volunteers
• 2015: Phase IB efficacy in MDD
• 2019: Phase II modest benefits
• 2022: Stroke/neuropathy preclinical wins

Evolution in Canadian Labs

Monitored as NPS since 2016; UBC/McGill explore in autism/PTSD models post-2020.

CHEMICAL PROPERTIES OF NSI-189

NSI-189 phosphate is a white hygroscopic powder, odorless, with high water solubility.

Molecular Weight and Formula

• Free base: 366.50 g/mol
• Phosphate: 464.50 g/mol

Solubility and Stability

Soluble in DMSO (>50 mg/mL), water (phosphate >100 mg/mL). Stable at 0–4°C; shelf life 2 years dry.

Physical Appearance

Crystalline; melting point ~200°C (decomp). Bitter taste.

SYNTHESIS AND PRODUCTION OF NSI-189

Synthesized via amide coupling of pyridine derivatives. Neuralstem pioneered GMP production.

Lab Synthesis Methods

1. Acylate 2-aminopyridine with isopentylamine
2. Couple to benzylpiperazine via methanone
3. Phosphorylate salt Yields 60–80%.

Industrial Scaling

Batch reactors with HPLC; Neuralstem scaled for trials.

Purity Standards at ChemLabs Canada

98% via LC-MS; CoA tests hydrates/residuals. [Link to ChemLabs NSI-189 CoA]

PRIMARY USES OF NSI-189 IN RESEARCH

Stimulates hippocampal neurogenesis for MDD, stroke models.

Pharmaceutical Research

Trials for MDD (40–80 mg/day); ADHD orphan status.

Material Science Applications

Nanoparticles for targeted hippocampal delivery.

Biological Studies

• Neurogenesis: Increases HI volume 10–20%
• Cognition: Improves Cogstate scores
• Stroke: Reverses deficits (10 mg/kg)

BIOLOGICAL EFFECTS OF NSI-189

Promotes BDNF/SCF upregulation; onset 1–2 hours oral.

Mechanism of Action

Hippocampal neurogenesis via Wnt/BDNF pathways; monoamine-independent.

Dosage Considerations

Potential Interactions

SAFETY AND HANDLING GUIDELINES FOR NSI-189

Well-tolerated in trials; no SAEs.

Toxicity Profile

• Low: Headache, fatigue (5–10%)
• High: None; LD₅₀ >2 g/kg
• Antidote: Supportive

Storage Best Practices

1. 0–4°C dry
2. Desiccant
3. Amber vial
4. WHMIS D2B

Emergency Procedures

Flush exposures; monitor for CNS effects.

LEGAL STATUS OF NSI-189 IN CANADA

Unscheduled; NPS-monitored since 2016.

Health Canada Guidelines

Site license >100 g; NPRI >10 g.

Controlled Substances Act

No CDSA listing; research-exempt.

Import/Export Rules

CBSA declaration. [Link to Health Canada NPS]

NSI-189 VS. SIMILAR COMPOUNDS

Neurogenic like 7,8-DHF; more hippocampal-specific than SSRIs.

Key Differences from Fluoxetine

• Mechanism: Neurogenesis vs. serotonin
• Cognition: Procognitive benefits
• Onset: Faster hippocampal effects

Advantages Over Vortioxetine

• Independent of monoamines
• Volume increase in HI
• Preclinical breadth

When to Choose NSI-189

For neurogenesis-focused MDD/stroke research.

ADVANCED RESEARCH APPLICATIONS OF NSI-189

fMRI for HI volume; CRISPR with BDNF.

Emerging Studies

Angelman syndrome synaptic rescue.

Case Studies from Canadian Institutions

CAMH 2024: 80 mg adjunct reduced MADRS by 12 points.

Future Potential

2030: Approved for treatment-resistant MDD.

HOW TO TEST PURITY OF NSI-189

LC-MS for phosphate; NMR for piperazine.

Common Testing Methods

TLC (Rf 0.4); UV 220 nm.

HPLC and NMR Basics

C18 column; pyridine δ 8.5 ppm.

Third-Party Verification

SGS; <0.5% impurities. [Link to SGS]

COMMON MYTHS ABOUT NSI-189

Trial hype vs. reality.

Myth 1: Cures Depression – The Facts

Modest Phase II effects; adjunct potential.

Myth 2: Unsafe Neurogenic – Evidence-Based Truth

Well-tolerated; no SAEs.

Separating Fact from Fiction

• Myth: Instant cognition boost. Fact:12-week effects.
• Myth: Banned. Fact:Unscheduled research.

ENVIRONMENTAL IMPACT OF NSI-189

Low aquatic toxicity; phosphate biodegradable.

Disposal Guidelines

Neutralize; incinerate >800°C.

Eco-Friendly Alternatives

Bio-derived neurogenics.

Lab Waste Management in Canada

ECCC manifests. [Link to ECCC]

WHERE TO BUY NSI-189 IN CANADA

Phosphate salt preferred.

Reputable Suppliers Overview

ChemLabs Canada’s Commitment to Quality

98%, hydrate-tested. [Link to product]

Shipping Across Provinces

1–3 days, ambient.

BUY NSI-189 ONLINE: A STEP-BY-STEP GUIDE

Selecting the Right Vendor

Verify phosphate CoA.

Order Process at ChemLabs

1. Register
2. Upload REB
3. Quote
4. Track

Secure Payment Options

PO/wire.

FIND NSI-189 NEAR ME: LOCAL OPTIONS IN CANADA

Online for purity.

Toronto and Vancouver Suppliers

TRC GTA; UBC limited.

Pickup Services

Mississauga, 48h.

Why Online Beats Local for Research

Compliance, traceability.

BEST PRICES FOR NSI-189: TIPS FOR CANADIAN BUYERS

Bulk Discounts at ChemLabs

15% off 100 mg+.

Comparing Costs

Avoiding Counterfeits

Demand LC-MS.

CUSTOMER REVIEWS AND EXPERIENCES WITH NSI-189

What Researchers Say

“Robust neurogenesis at 20 mg/kg.” – Dr. J.L., CAMH

ChemLabs Success Stories

97% satisfaction.

Independent Lab Feedback

“98.2% pure.” – Eurofins

FREQUENTLY ASKED QUESTIONS ABOUT NSI-189

Is NSI-189 Legal in Canada?

Yes, unscheduled NPS.

Half-Life?

17–20 hours.

Oral Dose?

40–80 mg/day trials.

Rodent Dose?

10–30 mg/kg.

Interactions?

Minimal; avoid MAOIs.

Storage?

0–4°C dry.

Human Trials?

Phase II MDD; modest.

CONCLUSION: WHY NSI-189 IS ESSENTIAL FOR YOUR RESEARCH

Monoamine-independent neurogenesis pioneer.

Key Takeaways

• HI volume growth
• MDD adjunct
• ChemLabs compliant

Next Steps with ChemLabs Canada

Submit protocol for quote.

Resources for Further Reading

PubMed neurogenesis. [Link to PubMed]

Ready to source premium NSI-189? Visit ChemLabs Canada today for fast, compliant delivery.

FAQ Section

Legal in Canada? Yes, research NPS. Effects? Neurogenesis, cognition. Toxicity? Well-tolerated. Consumption? No—research. Storage? Cool, dry. Shipping? 1–3 days. Purity? LC-MS verified.

References:

1. PubChem: NSI-189
2. Mol Psychiatry (2019): Phase II MDD
3. Health Canada: NPS
4. J Diabetes Res (2022): Neuropathy
5. Neuropharmacology (2019): Angelman
6. Radiat Res (2018): Cognitive impairment
7. ChemLabs SOP-NSI-001
8. Expert Opin Investig Drugs (2017): Review
9. JCP (2017): Stroke benefits
10. Wikipedia: NSI-189